RxSightRXST
RXST
About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Employees: 498
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3,444% more call options, than puts
Call options by funds: $8.04M | Put options by funds: $227K
94% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 48
1.96% more ownership
Funds ownership: 87.65% [Q4 2024] → 89.61% (+1.96%) [Q1 2025]
9% less funds holding
Funds holding: 212 [Q4 2024] → 192 (-20) [Q1 2025]
25% less capital invested
Capital invested by funds: $1.21B [Q4 2024] → $916M (-$298M) [Q1 2025]
43% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 42
67% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 1 (-2) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
13%
upside
Avg. target
$23
63%
upside
High target
$36
153%
upside
7 analyst ratings
3 positive
43%
3 neutral
43%
1 negative
14%
Wells Fargo Larry Biegelsen | 76%upside $25 | Overweight Upgraded | 19 May 2025 |
Piper Sandler Adam Maeder | 27%upside $18 | Neutral Initiated | 15 Apr 2025 |
UBS Danielle Antalffy | 13%upside $16 | Neutral Downgraded | 9 Apr 2025 |
Needham David Saxon | 55%upside $22 | Buy Maintained | 8 Apr 2025 |
JP Morgan Robbie Marcus | 20%upside $17 | Underweight Downgraded | 4 Apr 2025 |
Financial journalist opinion
Positive
Seeking Alpha
1 week ago
RxSight: Valuation Blowout Creates Opportunity
RxSight is a promising growth stock in the medical device sector, focusing on innovative cataract treatments with a large addressable market. Despite a recent decline, RxSight's high margins and scalable technology make it an attractive long-term investment, especially with expected 20% revenue growth in 2025. The stock's valuation has dropped from 20x to 4x trailing sales over the past year, presenting a potential buying opportunity for long-term investors.
Neutral
GlobeNewsWire
3 weeks ago
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum.
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
Seeking Alpha
1 month ago
RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer David Saxon - Needham & Company Adam Maeder - Piper Sandler Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Craig Bijou - Bank of America Tom Stephan - Stifel Operator Thank you for standing by. At this time, I would like to welcome everyone to the RxSight First Quarter 2025 Earnings Conference Call.
Negative
Zacks Investment Research
1 month ago
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.12 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
RxSight, Inc. to Present at the Bank of America Healthcare Conference
ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas.
Negative
Zacks Investment Research
1 month ago
RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Negative
Seeking Alpha
2 months ago
RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade)
RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism was premature. The competitive landscape has intensified with new IOL products from Johnson & Johnson and Rayner, challenging RxSight's unique LAL technology.
Neutral
Seeking Alpha
2 months ago
RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript)
RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Preliminary Results Conference Call April 3, 2025 8:00 AM ET Company Participants Oliver Moravcevic - VP, IR Dr. Ron Kurtz - Director, Co-President and CEO Shelley Thunen - Assistant Secretary, Co-President and CFO Conference Call Participants Ryan Zimmerman - BTIG Xuyang Li - Jefferies Robert Marcus - JPMorgan Steve Lichtman - Oppenheimer David Saxon - Needham Danielle Antalffy - UBS Operator Thank you for standing by, and welcome to the RxSight conference call. All lines have been placed on mute to prevent any background noise.
Neutral
GlobeNewsWire
2 months ago
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time.
Charts implemented using Lightweight Charts™